Healthcare Reform Legislation: New Drug Sample Reporting Requirement Packs 3 Compliance Concerns

Why This Topic Matters

The reporting change may give federal agencies more visibility into sample distribution and make documentation practices more important in audits and investigations. It matters because physician offices may need to review internal tracking, recordkeeping, and compliance policies for sample handling.

Article Sections

1. More transparency in billing investigations

   Discusses how sample reporting may affect scrutiny of billing and recordkeeping practices in physician offices. The section also addresses compliance concerns tied to documentation and patient records.

2. Beneficiary inducement issues

   Covers concerns about how sample distribution could be viewed in relation to patient referrals and office visit incentives. The section also notes documentation and policy considerations for practice management.

3. Potential anti-kickback implications

   Addresses general compliance concerns involving relationships between physicians and pharmaceutical manufacturers. The section focuses on the broader legal risk area associated with sample-related interactions.